<DOC>
	<DOCNO>NCT00102726</DOCNO>
	<brief_summary>SB497115 oral agent activate thrombopoietin receptor increase platelet count healthy volunteer . This study examine several different dos SB497115 versus placebo treatment patient advance solid tumor schedule receive chemotherapy carboplatin paclitaxel every 21 day . Patients receive SB497115 day 2-11 21 day cycle least 2 cycle chemotherapy maximum 8 cycle chemotherapy .</brief_summary>
	<brief_title>SB-497115 ( Oral Thrombopoietin Receptor Agonist ) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy</brief_title>
	<detailed_description>A Double-Blind , Randomized , Multicenter , Placebo-Controlled , Parallel Group , Dose Ranging Study Assess Efficacy , Safety , Pharmacokinetics Oral Thrombopoietin Receptor Agonist ( SB-497115-GR ) Administered 50 , 75 , 100 mg Cancer Patients Receiving Multiple Cycles Chemotherapy</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Inclusion criterion : Subjects ≥18 year old , chemotherapy naïve , histologically cytologically confirm advanced solid tumor ( leukemia lymphoma exclude ) schedule receive carboplatin/paclitaxel show . For purpose study , advance tumor define tumor treat palliative intent ( i.e. , treat curative intent ) . Subjects schedule receive firstline chemotherapy carboplatin AUC 56 IV 30 minute plus paclitaxel 175225 mg/m2 IV 3 hour day 1 every 21 day , routine premedications , i.e. , 20 mg dexamethasone [ equivalent ] orally 6 12 hour prepaclitaxel , 50 mg IV diphenhydramine [ equivalent ] 300 mg IV cimetidine [ equivalent ] 3060 minute prepaclitaxel . ECOGZubrod performance status 0 , 1 . Subject history platelet disorder dysfunction history bleeding disorder . Subjects adequate : hematologic function ( ANC ≥ 1,500/mm3 , hemoglobin ≥ 9 g/dL , platelet count ≥100,000/mm3 &lt; upper limit normal range ( eg , 400,000 450,000/mm3 ) , hepatic function ( bilirubin ≤ 2 mg/dL alanine aminotransferase ≤ three time upper limit normal ) , renal function ( creatinine ≤ 2.0 mg/dL ) . Subject physical limitation ingest retain oral medication . Subject life expectancy least 6 month . Subject practice acceptable method contraception ( documented chart ) . Female subject ( female partner male subject ) must either nonchildbearing potential ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation postmenopausal &gt; 1 year ) , childbearing potential use one follow acceptable method contraception two week prior administration study medication , throughout study , 28 day completion premature discontinuation study : Complete abstinence intercourse ; Intrauterine device ( IUD ) ; Two form barrier contraception ( diaphragm plus spermicide , male condom plus spermicide ) ; Male partner sterile prior entry study partner female ; Systemic contraceptive ( combine progesterone ) . Subject able understand comply protocol requirement instruction intend complete study plan . Subject sign dated write informed consent . Chemotherapy naive patient advance solid tumor ( without brain metastasis rapid progression within 2 week ) schedule receive standard firstline therapy carboplatin paclitaxel every 21 day . Adequate hematologic , hepatic renal function . Exclusion criterion : Any clinically relevant abnormality , cancer , identify screen examination , medical condition circumstance , opinion Investigator , make subject unsuitable participation study and/or would make patient 's data difficult interpret . Subjects know history rapidly progressive disease ( marked increase tumor size [ &gt; 50 % ] , ascites , serious symptom relate underlying cancer precede 4week period ) , surgery within previous 2 week , radiotherapy within previous 4 week , prior chemotherapy . Subjects know preexist cardiac disease , include congestive heart failure , arrhythmias require treatment , myocardial infarction within precede 3 month . Subjects abnormal rest 12lead ECG screen would indicate preexist cardiac disease , note exclusion criterion 3 . Subjects know clot disorder associate hypercoaguability . Subject consume aspirin , aspirincontaining compound , salicylate , quinine nonsteroidal antiinflammatories ( NSAIDs ) &gt; 3 consecutive day within 2 week study start would require time study . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication . Subject consume liquid antacid ( e.g . Maalox , Mylanta , Amphogel , milk magnesia ) , chewable antacid ( e.g . TUMS ) calcium supplement within 48 hour first dose study medication , and/or require medication study . Subject consume rosuvastatin pravastatin within 1 week first dose study medication and/or require medication time study . Any history druginduced thrombocytopenia ( e.g. , quinine ) . Systemic anticoagulant use within 4 week prior study entry . Consumption herbal dietary supplement , exclude vitamin mineral supplement ( See Exclusion 8 calcium supplement ) , within 1 week study start . Female subject lactate positive betahCG screening . Subjects history CNS metastases clinical sign symptom brain and/or leptomeningeal metastasis confirm CT MRI brain scan . History platelet bleed disorder . Patients use aspirin , aspirincontaining compound , salicylate , antacid , rosuvastatin , pravastatin , nonsteroidal antiinflammatory drug great 3 day within 3 week prior study . Females pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chemotherapy</keyword>
	<keyword>thrombopoietin</keyword>
	<keyword>platelet</keyword>
	<keyword>chemotherapy induce</keyword>
</DOC>